Bosentan in mild pulmonary hypertension

The Lancet

Volumn 372, Issue 9651, 2008, Pages 1730-1731

  Giannakoulas, Georgios ^a   Dimopoulos, Konstantinos ^a   Gatzoulis, Michael A ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ANTIHYPERTENSIVE AGENT; SULFONAMIDE;

CLINICAL RESEARCH; CLINICAL TRIAL; CONGENITAL HEART DISEASE; EISENMENGER COMPLEX; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESEARCH SUBJECT; NOTE; PATHOPHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; SULFONAMIDES;

EID: 55749098627     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61726-2     Document Type: Letter

References (5)

1. Galie N., Rubin L.J., Hoeper M.M., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371 (2008) 2093-2100
2. Dimopoulos K., Diller G.P., Koltsida E., et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation 117 (2008) 2320-2328
3. Spence M.S., Balaratnam M.S., and Gatzoulis M.A. Clinical update: cyanotic adult congenital heart disease. Lancet 370 (2007) 1530-1532
4. Diller G.P., Dimopoulos K., Kafka H., Ho S., and Gatzoulis M.A. Model of chronic adaptation: right ventricular function in Eisenmenger syndrome. Eur Heart J 9 suppl (2007) H54-H60
5. Diller G.P., Dimopoulos K., Broberg C.S., et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 27 (2006) 1737-1742